Lei Xiang, Wei Zhili, Liu Shidong, Liang Fuxiang, Song Bing
First Clinical Medical College, Lanzhou University.
Department of Cardiovascular Surgery, First Hospital of Lanzhou University, Lanzhou, China.
Medicine (Baltimore). 2020 Feb;99(9):e19307. doi: 10.1097/MD.0000000000019307.
Transcatheter aortic valve replacement (TAVR) has become an essential alternate option for people suffering from aortic stenosis. However, the efficacy and safety of TAVR for elderly population (aged over 80 years) is still unclear.
We plan to perform a systematic review and meta-analysis of clinical controlled trials and propensity-match cohort studies to evaluate the short- and long-term outcomes in elderly aortic stenosis patients who undergo a transcatheter or surgical aortic valve replacement. We will search PubMed, EMBASE, and Cochrane Library using a comprehensive strategy. The related conference proceedings and reference lists of the included studies will also be checked to identify additional studies. Two reviewers will screen retrieved records, extract information, and assess the risk of bias independently. STATA software will be used to conduct data synthesis. There is no requirement of ethical approval and informed consent.
This study will be submitted to a peer-reviewed journal for publication.
This is the first systematic assessment of TAVR for elderly patients with aortic stenosis. We hope it will provide a relatively comprehensive reference for clinical practice and future relevant clinical trials.
Ethics approval and patient consent are not required as this study is a systematic review and meta-analysis.
CRD42019140857.
The protocol has been registered in PROSPERO, which is an International Prospective Register of Systematic Reviews. The registration number is CRD42019140857.
经导管主动脉瓣置换术(TAVR)已成为主动脉瓣狭窄患者的重要替代选择。然而,TAVR 用于老年人群(80 岁以上)的疗效和安全性仍不明确。
我们计划对临床对照试验和倾向匹配队列研究进行系统评价和荟萃分析,以评估接受经导管或外科主动脉瓣置换术的老年主动脉瓣狭窄患者的短期和长期结局。我们将采用综合策略检索 PubMed、EMBASE 和考克兰图书馆。还将检查纳入研究的相关会议论文集和参考文献列表,以识别其他研究。两名审阅者将独立筛选检索到的记录、提取信息并评估偏倚风险。将使用 STATA 软件进行数据合成。无需伦理批准和知情同意。
本研究将提交给同行评审期刊发表。
这是对老年主动脉瓣狭窄患者 TAVR 的首次系统评估。我们希望它能为临床实践和未来相关临床试验提供较为全面的参考。
由于本研究是一项系统评价和荟萃分析,因此无需伦理批准和患者同意。
PROSPERO 注册号:CRD42019140857。
该方案已在 PROSPERO 注册,PROSPERO 是一个国际前瞻性系统评价注册库。注册号为 CRD42019140857。